Xeris Biopharma stockholders elect directors, ratify auditor at 2026 annual meeting

Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected Dawn Halkuff and John Johnson as Class II directors to serve until 2029, with Halkuff receiving 71.5% support and Johnson 60.2% of votes cast.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 98.1% approval, continuing the firm's engagement.

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved on advisory basis with 94.3% support among votes cast, indicating stockholder satisfaction with pay structure.

  Item 5.07 verify on EDGAR →